Desvenlafaxine Tablet, Extended Release
Product Images NDC 72888-144

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 72888-144). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Desvenlafaxine Extended-release Tablets 100 mg (NDC 72888-144-00)

Label for Desvenlafaxine Extended-Release Tablets 100 mg by Advagen Pharma Ltd. The label indicates the product contains 100 mg desvenlafaxine per extended-release tablet, with package quantity of 1000 tablets. Distributed by Advagen Pharma Limited, USA, and manufactured by Rubicon Research Private Limited in India. Includes storage instructions and a medication guide URL.*

FDA Label Image

Desvenlafaxine Extended-release Tablets 100 mg (NDC 72888-144-30)

Label for Desvenlafaxine Extended-Release Tablets, 100 mg, manufactured by Advagen Pharma Ltd and Rubicon Research Private Limited. This film-coated, extended-release tablet contains 100 mg of desvenlafaxine per tablet with a package size of 30 tablets. Storage instructions specify controlled room temperature between 20° to 25°C. The label includes directions to swallow tablets whole and a medication guide URL.*

FDA Label Image

Desvenlafaxine Extended-release Tablets 100 mg (NDC 72888-144-05)

Label for Desvenlafaxine Extended-Release Tablets 100 mg, showing the product name, dosage form, strength, quantity of 500 tablets, and Rx only status. The label indicates Advagen Pharma Limited as distributor and Rubicon Research Private Limited as manufacturer. Additional text includes storage instructions and a medication guide website.*

FDA Label Image

Desvenlafaxine Extended-release Tablets 100 mg (NDC 72888-144-90)

Label for Desvenlafaxine Extended-Release Tablets, 100 mg, oral tablet formulation by Advagen Pharma Ltd. This packaging contains 90 tablets. The label includes storage instructions, distributor and manufacturer information, and a medication guide link. The product is prescription only (Rx).*

FDA Label Image

Desvenlafaxine Extended-release Tablets 50 mg (NDC 72888-143-00)

Desvenlafaxine Extended-Release Tablets 50 mg label showing a 1000-tablet package. The label highlights the active ingredient strength, storage instructions, distributor Advagen Pharma Limited, and manufacturer Rubicon Research Private Limited. It includes a barcode and medication guide information.*

FDA Label Image

Desvenlafaxine Extended-release Tablets 50 mg (NDC 72888-143-30)

Desvenlafaxine Extended-Release Tablets 50 mg label showing a 30-tablet bottle package. The label includes storage instructions to keep at 20° to 25°C, directions to swallow tablets whole, and warnings to keep out of reach of children. Distributed by Advagen Pharma Limited and manufactured by Rubicon Research Private Limited.*

FDA Label Image

Desvenlafaxine Extended-release Tablets 50 mg (NDC 72888-143-05)

Label for Desvenlafaxine Extended-Release Tablets 50 mg by Advagen Pharma Ltd. The oral tablet is available in a 500 count package. Distributed by Advagen Pharma Limited, Plainsboro, NJ, and manufactured by Rubicon Research Private Limited, India. The label includes dosing warnings, storage instructions, and a medication guide URL.*

FDA Label Image

Desvenlafaxine Extended-release Tablets 50 mg (NDC 72888-143-90)

Label for Desvenlafaxine Extended-Release Tablets 50 mg, oral tablet dosage form. The label shows a 90-tablet count and states prescription-only use. Distributed by Advagen Pharma Limited and manufactured by Rubicon Research Private Limited in India. Includes storage instructions and a barcode.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 1)

A forest plot showing the geometric mean ratios with 90% confidence intervals for Cmax and AUC of Desvenlafaxine in subjects with varying degrees of renal and hepatic impairment, and demographic groups by gender and age. The x-axis indicates change relative to the reference group, ranging from 0.5 to 3.5.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 2)

A chart showing the geometric mean ratio with 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of DESVENLAFAXINE when co-administered with the CYP3A4 inhibitor ketoconazole. The x-axis represents change relative to reference, ranging from 0.50 to 2.0. The chart indicates moderate effect on AUC and minimal effect on Cmax.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 3)

A chart showing the geometric mean ratio with 90% confidence intervals for various pharmacokinetic (PK) parameters such as Cmax and AUC of drugs interacting with desvenlafaxine. It includes data for substrates CYP2D6 and CYP3A4, showing interactions with drugs like desipramine, midazolam, tamoxifen, and aripiprazole at different dosages, illustrating changes relative to reference values.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 4)

A Kaplan-Meier curve showing the estimated proportion of patients experiencing relapse over time (days from randomization) comparing Desvenlafaxine 50 mg (solid blue line) versus placebo (dashed red line). The y-axis represents the estimated proportion of patients with relapse in percentage, and the x-axis represents the time to relapse in days up to about 200 days.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 5)

A Kaplan-Meier curve illustrating the estimated proportion of patients with relapse over time in days from randomization. The graph compares desvenlafaxine (solid blue line) and placebo (dashed red line), showing relapse proportions on the vertical axis and time to relapse on the horizontal axis.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Structure)

Chemical structure diagram of desvenlafaxine, showing its molecular components including a phenol group, tertiary amine, hydroxyl groups, carboxylic acid groups, and a water molecule as part of the structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.